Bicycle Therapeutics Ltd
$ 4.20
-1.64%
05 Jun - close price
- Market Cap 293,207,000 USD
- Current Price $ 4.20
- High / Low $ 4.29 / 4.08
- Stock P/E N/A
- Book Value 7.95
- EPS -3.15
- Next Earning Report 2026-08-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.19 %
- ROE -0.34 %
- 52 Week High 9.36
- 52 Week Low 4.08
About
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments. The company is headquartered in Cambridge, the United Kingdom.
Analyst Target Price
$12.11
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-03-17 | 2025-10-30 | 2025-08-08 | 2025-05-01 | 2025-02-25 | 2024-10-31 | 2024-08-06 | 2024-05-02 | 2024-02-20 | 2023-11-02 | 2023-08-03 |
| Reported EPS | -0.87 | -0.29 | -0.85 | -1.14 | -0.88 | -0.8144 | -0.72 | -0.77 | -0.62 | -1.16 | -1.26 | -1.41 |
| Estimated EPS | -0.67 | -0.9372 | -1.07 | -0.93 | -0.85 | -0.8536 | -0.78 | -1.11 | -1.21 | -1.23 | -1.06 | -1.07 |
| Surprise | -0.2 | 0.6472 | 0.22 | -0.21 | -0.03 | 0.0392 | 0.06 | 0.34 | 0.59 | 0.07 | -0.2 | -0.34 |
| Surprise Percentage | -29.8507% | 69.0568% | 20.5607% | -22.5806% | -3.5294% | 4.5923% | 7.6923% | 30.6306% | 48.7603% | 5.6911% | -18.8679% | -31.7757% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-07 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.58 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BCYC
2026-05-21 23:39:41
Bicycle Therapeutics will present initial data from its randomized Phase 2 Duravelo-2 trial and updated Phase 1 Duravelo-1 trial data at the 2026 ASCO Annual Meeting. The data shows that zelenectide pevedotin (zelenectide) in combination with pembrolizumab achieved encouraging response rates and a potentially differentiated safety profile in patients with previously untreated metastatic urothelial cancer (mUC), with lower rates of neuropathy and skin toxicities compared to standard of care. The company expects to release further Duravelo-2 data in the second half of 2026.
2026-05-21 21:39:48
Bicycle Therapeutics announced promising initial data from its Duravelo-2 and updated Duravelo-1 trials for zelenectide pevedotin in metastatic urothelial cancer (mUC). The data showed comparable response rates to standard of care with a potentially differentiated safety profile, including significantly lower incidence of skin reactions and peripheral neuropathy. Further results from the Duravelo-2 trial are anticipated in the second half of 2026, and the findings will be presented at the 2026 ASCO Annual Meeting.
2026-05-21 21:39:05
Bicycle Therapeutics announced initial Duravelo-2 data for zelenectide in metastatic urothelial cancer, showing comparable response rates and a potentially differentiated safety profile. Data from Duravelo-2 and updated Duravelo-1 trials highlighted high objective response rates (ORR), sustained treatment duration, and low incidence of severe adverse events. These results suggest zelenectide could be a promising treatment option for mUC with favorable toxicity.
2026-05-21 20:39:05
Bicycle Therapeutics announced initial data from its Phase 2 (Duravelo-2) trial and updated data from its Phase 1 (Duravelo-1) trial for zelenectide pevedotin in metastatic urothelial cancer (mUC). The drug, in combination with pembrolizumab, showed comparable response rates to standard of care but with significantly fewer skin reactions (four-fold lower) and half the peripheral neuropathy. Bicycle Therapeutics believes these results validate its technology's potential for oncology therapeutics with improved benefit/risk profiles.
2026-05-21 20:39:05
Bicycle Therapeutics (NASDAQ: BCYC) has released initial Duravelo-2 and updated Duravelo-1 clinical data for zelenectide pevedotin in metastatic urothelial cancer. The data indicate response rates and progression-free survival comparable to standard-of-care, alongside a potentially improved safety profile with lower rates of skin reactions and peripheral neuropathy. Further randomized Phase 2 data from the Duravelo-2 trial are anticipated in the second half of 2026.
2026-05-15 15:08:51
Armistice Capital, LLC and Steven Boyd have disclosed a 6.75% beneficial ownership stake in Bicycle Therapeutics (BCYC), totaling 3,398,000 American Depositary Shares (ADS) via a SCHEDULE 13G/A SEC filing. Armistice Capital, as the investment manager for a Master Fund, exercises shared voting and dispositive power over these shares. The filing indicates the shares are held in the ordinary course of business and not for influencing control of the issuer.
